Apellis’ Syfovre Receives the US FDA’s Approval as the First Treatment for Geographic Atrophy
Shots:
- The US FDA has approved Syfovre (pegcetacoplan injection) for GA secondary to AMD. The approval was based on the P-III (OAKS) & (DERBY) studies evaluating the efficacy & safety of Syfovre
- The results showed a reduction in the rate of GA lesion growth vs sham and demonstrated increasing treatment effects over time with the greatest benefit, ~36% reduction in lesion growth with monthly treatment in (DERBY) b/w 18-24mos.
- The company launched the patient support program i.e., ApellisAssist incl. insurance support, financial assistance, disease education & ongoing product support for eligible patients. The MAA for Syfovre is currently under EMA’s review with an expected decision in early 2024
Ref: GlobeNewswire | Image: Apellis
Related Post:- Apellis Presents 24-Month P-III (OAKS) Post Hoc Results of Pegcetacoplan for the Treatment of Geographic Atrophy at AAO 2022
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
